Described herein are crystalline forms of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof. Also described herein are pharmaceutical formulations of 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, and pharmaceutically acceptable salts and solvates thereof.

The present invention discloses a polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or a solvate thereof, and use thereof in preparing novel feed additives and feed; the present invention also discloses a composition comprising the polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or the solvate thereof. The polyvalent metal ion compound salt of N,N-dimethylglycine and organic acid or the solvate thereof provided by the present invention has improvement effect on animal product performance such as improving animal weight gain and reducing feed conversion ratio, showing effects similar to or higher than that of sodium N,N-dimethylglycinate.

Abexinostat tosylate of formula (II):

##STR00001##

and its crystalline form I characterised by its X-ray powder diffraction diagram, its Raman spectrum and its solid-state .sup.13C CP/MAS NMR spectrum.

Medicinal products containing the same which are useful in the treatment of cancer.

Abexinostat tosylate of formula (II):

##STR00001##

and its crystalline form I characterised by its X-ray powder diffraction diagram, its Raman spectrum and its solid-state .sup.13C CP/MAS NMR spectrum.

Medicinal products containing the same which are useful in the treatment of cancer.

The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans.

The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans.

A capacitor and a method of making a capacitor, is provided with improved reliability performance. The capacitor comprises an anode; a dielectric on the anode; and a cathode on the dielectric wherein the cathode comprises a conductive polymer and a polyanion wherein the polyanion is a copolymer comprising groups A, B and C represented by Formula A.sub.xB.sub.yC.sub.z as described herein.

The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase.

Disclosed is a non-linear optical crystal containing pyridinium represented by the following Formula (1), 4-substituted phenylsulfonate represented by the following Formula (2a), and 2,4,6-substituted phenylsulfonate represented by the following Formula (2b).

##STR00001##

Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are further described.